TR201906773T4 - Amilin-mimetik bileşikleri ile polietilenglikolün aglomera olmayan biyokonjugatları. - Google Patents

Amilin-mimetik bileşikleri ile polietilenglikolün aglomera olmayan biyokonjugatları. Download PDF

Info

Publication number
TR201906773T4
TR201906773T4 TR2019/06773T TR201906773T TR201906773T4 TR 201906773 T4 TR201906773 T4 TR 201906773T4 TR 2019/06773 T TR2019/06773 T TR 2019/06773T TR 201906773 T TR201906773 T TR 201906773T TR 201906773 T4 TR201906773 T4 TR 201906773T4
Authority
TR
Turkey
Prior art keywords
bioconjugates
amylin
agglomerated
polyethylene glycol
mimetic compounds
Prior art date
Application number
TR2019/06773T
Other languages
English (en)
Inventor
Mauricio Trambaioli Da Rocha E Lima Luis
Henrique Guerreiro Rosado Luiz
Fernandes De Avila Netto Guterres Mariana
Melo Vieira Gonçalves Ferreira Bruno
Original Assignee
Univ Rio De Janeiro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rio De Janeiro filed Critical Univ Rio De Janeiro
Publication of TR201906773T4 publication Critical patent/TR201906773T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)

Abstract

Mevcut buluş genel olarak polietilen glikol ile amilin-mimetik bileşiklerinin yeni aglomera olmayan biyo-konjugatları ile ve bunların esas olarak pankreas gibi sistemik organların işlev bozukluğuna veya yetersizliğine katkıda bulunan, hücre dışı amiloid depolanması veya birikimi ile bağlantılı hastalıkların tedavisinde kullanımı ile ilgilidir.
TR2019/06773T 2013-06-14 2014-06-13 Amilin-mimetik bileşikleri ile polietilenglikolün aglomera olmayan biyokonjugatları. TR201906773T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRBR102013017626-5A BR102013017626A2 (pt) 2013-06-14 2013-06-14 Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.

Publications (1)

Publication Number Publication Date
TR201906773T4 true TR201906773T4 (tr) 2019-05-21

Family

ID=52021510

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/06773T TR201906773T4 (tr) 2013-06-14 2014-06-13 Amilin-mimetik bileşikleri ile polietilenglikolün aglomera olmayan biyokonjugatları.

Country Status (13)

Country Link
US (2) US20160331811A1 (tr)
EP (1) EP3007721B1 (tr)
JP (1) JP2016526533A (tr)
CN (1) CN105658234A (tr)
AU (1) AU2014280869B2 (tr)
BR (1) BR102013017626A2 (tr)
CA (1) CA2915104A1 (tr)
ES (1) ES2720274T3 (tr)
MX (1) MX368485B (tr)
PL (1) PL3007721T3 (tr)
PT (1) PT3007721T (tr)
TR (1) TR201906773T4 (tr)
WO (1) WO2014197961A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102015031283A2 (pt) * 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
US10609584B2 (en) * 2016-08-12 2020-03-31 Telefonaktiebolaget Lm Ericsson (Publ) Selection of a carrier in multi-carrier operation system

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
AU2003235742B2 (en) * 2002-01-08 2008-08-07 Amylin Pharmaceuticals, Llc Use of Amylin agonists to modulate triglycerides
CA2501677A1 (en) * 2002-10-22 2004-05-06 Waratah Pharmaceuticals, Inc. Treatment of diabetes
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8114958B2 (en) * 2004-02-11 2012-02-14 Amylin Pharmaceuticals, Inc. Amylin family peptides
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US7879794B2 (en) * 2005-03-31 2011-02-01 Amylin Pharmaceuticals, Inc. Methods for controlling binge eating disorders
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
JP2008536881A (ja) * 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Ｇｌｐ−１分子と制吐剤との医薬製剤
EP1996617A2 (en) * 2006-03-15 2008-12-03 Novo Nordisk A/S Amylin derivatives
EP2102355B1 (en) * 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
JP2011520447A (ja) * 2008-05-16 2011-07-21 ネクター セラピューティックス コリンエステラーゼ部分とポリマーとのコンジュゲート
EP2300037B1 (en) * 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
AU2009292643B2 (en) * 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
BRPI1003424A2 (pt) * 2010-09-08 2013-01-08 Univ Rio De Janeiro sistema polimÉtrico de confinamento de amilina humana e anÁlogos agonistas, processo e uso; processo de avaliaÇço funcional de amilina liberada
IL295201A (en) * 2010-11-12 2022-10-01 Nektar Therapeutics Conjugations of a part of il-2 and a polymer, preparations containing them and their uses
WO2012162547A2 (en) * 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
JP6040464B2 (ja) * 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
US20140249076A1 (en) * 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
US9830621B2 (en) * 2013-03-14 2017-11-28 Vdopia Inc. Systems and methods for layering content

Also Published As

Publication number Publication date
US20160331811A1 (en) 2016-11-17
PT3007721T (pt) 2019-05-13
CN105658234A (zh) 2016-06-08
JP2016526533A (ja) 2016-09-05
EP3007721B1 (en) 2019-02-27
BR102013017626A2 (pt) 2015-02-10
PL3007721T3 (pl) 2019-09-30
AU2014280869A1 (en) 2016-01-07
WO2014197961A1 (en) 2014-12-18
US20160184401A1 (en) 2016-06-30
ES2720274T3 (es) 2019-07-19
EP3007721A1 (en) 2016-04-20
MX368485B (es) 2019-10-04
EP3007721A4 (en) 2016-12-07
CA2915104A1 (en) 2014-12-18
AU2014280869B2 (en) 2017-11-02
MX2015017356A (es) 2016-12-20
WO2014197961A9 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
EA201892386A1 (ru) Химерные нейротоксины
GT201700033A (es) Anticuerpos anti tigit
ECSP17021754A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
MX2015017532A (es) Métodos para modular la actividad del regulador de transmembrana de fibrosis quística.
UA118558C2 (uk) Пептидна сполука
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
EA201391392A1 (ru) Синтетические наноносители с осмотически опосредованным высвобождением
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2015002897A1 (es) Inhibidores de bace1
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UY35747A (es) Derivados sustituidos de fenilalanina
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
EA201890212A1 (ru) Новое применение сульфата декстрана
CL2016002839A1 (es) Derivados de carboxamida
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
UY35745A (es) Derivados sustituidos de fenilalanina